Cancer
| 3 min read
The therapy exploits the properties of a neutrophil-derived enzyme to selectively kill tumor cells while preserving healthy immune cells.
| 2 min read
Researchers highlight how intra-tumoral microbiota shape tumor growth, drug resistance, and treatment response.
| 3 min read
Ryvu’s ONCO Prime platform uncovers novel molecular vulnerabilities and actionable targets in colorectal and other cancers.
| 4 min read
Multibillion dollar oncology deals, first-in-class wins, AI scientists, and more led the news this week.
| 3 min read
A new study showed that adding a drug to inhibit the OPA1 protein could reverse resistance to a frontline treatment in patients with AML.
| 4 min read
Positive results for a radioligand therapy, a billion-dollar deal for a MASH drug, the Nobel Prize for immune system research, and more led the news this week.
| 3 min read
Structural insights reveal how DCAF2 can be harnessed to target previously untouchable proteins for degradation.
| 9 min read
Scientists are advancing CAR T cell therapy to improve outcomes for children with acute lymphoblastic leukemia.
| 3 min read
The POSEIDON program aims to create first-in-class synthetic sensor-based tests to detect over 30 cancers at Stage I using only non-invasive breath and urine samples.
| 2 min read
Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts
| 5 min read
Advances in allosteric inhibitors may offer a new standard of care that balances potent disease control with better tolerability and convenience.
| 3 min read
Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.
